BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 15534620)

  • 1. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
    Ihle CL; Provera MD; Straign DM; Smith EE; Edgerton SM; Van Bokhoven A; Lucia MS; Owens P
    J Immunother Cancer; 2019 Nov; 7(1):293. PubMed ID: 31703602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.
    Parimi S; Bondy S; Tsang E; McKenzie MR; Bachand F; Aparicio M; Duncan G; Sunderland K; Olson RA; Pai HH; Alexander AS; LaPointe V; Chi KN; Tyldesley S
    Can Urol Assoc J; 2019 Oct; 13(10):E311-E316. PubMed ID: 31364977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.
    Muralidharan A; Smith MT
    Inflammopharmacology; 2013 Oct; 21(5):339-63. PubMed ID: 23918298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.
    Aapro M; Saad F
    Ther Adv Urol; 2012 Apr; 4(2):85-101. PubMed ID: 22496711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases.
    Matza LS; Fallowfield LJ; Chung KC; Currie BM; Van Brunt K; Patrick DL
    Support Care Cancer; 2012 Apr; 20(4):657-77. PubMed ID: 22302082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study.
    Rodrigues P; Hering FO; Meller A
    Cancer Res Treat; 2011 Dec; 43(4):231-5. PubMed ID: 22247708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bisphosphonates on pain and quality of life in patients with bone metastases.
    Costa L; Major PP
    Nat Clin Pract Oncol; 2009 Mar; 6(3):163-74. PubMed ID: 19190592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of skeletal complications on patients' quality of life, mobility, and functional independence.
    Costa L; Badia X; Chow E; Lipton A; Wardley A
    Support Care Cancer; 2008 Aug; 16(8):879-89. PubMed ID: 18392862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
    J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
    Rodrigues P; Hering F; Campagnari JC
    Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
    Heidenreich A; Hofmann R; Engelmann UH
    J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
    Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
    Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
    Vorreuther R; Klotz T; Engelking R
    Urologe A; 1992 Mar; 31(2):63-6. PubMed ID: 1373255
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.